Business
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists
LA JOLLA, Calif., May 06, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu, Hawaii, May 3 – 7.
About this update from Equillium, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/business-wire.com/95f6b65c33e6bf8a4ce4d2dcbbff2cca"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uRexNkFDrjAbzpir377SgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/95f6b65c33e6bf8a4ce4d2dcbbff2cca","width":400,"height":400}},"lazy":false},{"type":"text","content":"EQ504 protects against gut damage in a mouse model of ulcerative colitis","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"EQ504 increases Treg stability and function while suppressing pathogenic Th17 responses","length":87,"tagName":"p","attribs":{}},{"type":"text","content":"EQ504 promotes healing of intestinal epithelial cells by promoting anti-inflammatory cytokines","length":94,"tagName":"p","attribs":{}},{"type":"text","content":"LA JOLLA, Calif., May 06, 2025--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu, Hawaii, May 3 – 7.","length":462,"tagName":"p"},{"type":"text","content":""Decades of independent research have validated AhR as an important physiological regulator of immune homeostasis in barrier tissues such as the gut," said Dr. Stephen Connelly, chief scientific officer at Equillium. "These data demonstrate the potent activity of EQ504 in suppressing inflammation and repair of intestinal tissues highlighting its potential as a powerful approach to treating ulcerative colitis, where poor mucosal healing limits the majority of patients achieving full clinical remission."","length":527,"tagName":"p"},{"type":"text","content":"Title: EQ504: A Novel AhR Agonist That Promotes Immune Tolerance Through Modulating T Cell FunctionAbstract Number: 4678Session Title: BA3P – Emerging Concepts in B Cell and T Cell Role in Autoimmune Disease IIPoster Number: P107Lead Author: Jeanette Ampudia, Director, Immunology & Research Operations...